全文获取类型
收费全文 | 1974篇 |
免费 | 117篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 66篇 |
妇产科学 | 20篇 |
基础医学 | 165篇 |
口腔科学 | 44篇 |
临床医学 | 146篇 |
内科学 | 472篇 |
皮肤病学 | 45篇 |
神经病学 | 67篇 |
特种医学 | 127篇 |
外科学 | 454篇 |
综合类 | 24篇 |
一般理论 | 2篇 |
预防医学 | 60篇 |
眼科学 | 104篇 |
药学 | 78篇 |
肿瘤学 | 214篇 |
出版年
2024年 | 6篇 |
2023年 | 25篇 |
2022年 | 63篇 |
2021年 | 147篇 |
2020年 | 57篇 |
2019年 | 108篇 |
2018年 | 97篇 |
2017年 | 58篇 |
2016年 | 78篇 |
2015年 | 92篇 |
2014年 | 122篇 |
2013年 | 151篇 |
2012年 | 180篇 |
2011年 | 187篇 |
2010年 | 85篇 |
2009年 | 71篇 |
2008年 | 101篇 |
2007年 | 110篇 |
2006年 | 86篇 |
2005年 | 78篇 |
2004年 | 63篇 |
2003年 | 59篇 |
2002年 | 43篇 |
2001年 | 2篇 |
2000年 | 1篇 |
1999年 | 8篇 |
1998年 | 6篇 |
1996年 | 3篇 |
1995年 | 1篇 |
1994年 | 2篇 |
1993年 | 3篇 |
1991年 | 3篇 |
1983年 | 1篇 |
排序方式: 共有2097条查询结果,搜索用时 31 毫秒
61.
Teena Singla I.K. Pandit Nikhil Srivastava Neeraj Gugnani Monika Gupta 《Saudi Dental Journal》2012,24(1):35-42
AimTo evaluate the microleakage of recently available glass ionomer based restorative materials (GC Fuji IX GP, GC Fuji VII, and Dyract) and compare their microleakage with the previously existing glass ionomer restorative materials (GC Fuji II LC) in primary and permanent teeth.MethodOne hundred and fifty (75 + 75) non-carious deciduous and permanent teeth were restored with glass ionomer based restorative materials after making class I cavities. Samples were subjected to thermocycling after storing in distilled water for 24 h. Two coats of nail polish were applied 1 mm short of restorative margins and samples sectioned buccolingually after storing in methylene blue dye for 24 h. Microleakage was assessed using stereomicroscope.ResultSignificant differences (P < 0.05) were found when inter group comparisons were done. Except when GC Fuji VII (Group III) was compared with GC Fuji II LC (Group II) and Dyract (Group IV), non-significant differences (P > 0.05) were observed. It was found that there was no statistically significant difference when the means of microleakage of primary teeth were compared with those of permanent teeth.ConclusionsGC Fuji IX GP showed maximum microleakage and GC Fuji VII showed least microleakage. 相似文献
62.
Farshid Amirabdollahian Salvatore Livatino Behrad Vahedi Radhika Gudipati Patrick Sheen Shan Gawrie-Mohan Nikhil Vasdev 《Journal of robotic surgery》2018,12(1):11-25
With the successful uptake and inclusion of robotic systems in minimally invasive surgery and with the increasing application of robotic surgery (RS) in numerous surgical specialities worldwide, there is now a need to develop and enhance the technology further. One such improvement is the implementation and amalgamation of haptic feedback technology into RS which will permit the operating surgeon on the console to receive haptic information on the type of tissue being operated on. The main advantage of using this is to allow the operating surgeon to feel and control the amount of force applied to different tissues during surgery thus minimising the risk of tissue damage due to both the direct and indirect effects of excessive tissue force or tension being applied during RS. We performed a two-rater systematic review to identify the latest developments and potential avenues of improving technology in the application and implementation of haptic feedback technology to the operating surgeon on the console during RS. This review provides a summary of technological enhancements in RS, considering different stages of work, from proof of concept to cadaver tissue testing, surgery in animals, and finally real implementation in surgical practice. We identify that at the time of this review, while there is a unanimous agreement regarding need for haptic and tactile feedback, there are no solutions or products available that address this need. There is a scope and need for new developments in haptic augmentation for robot-mediated surgery with the aim of improving patient care and robotic surgical technology further. 相似文献
63.
Marshall Colin Enzerra Michael Rahnemai-Azar Amir Ata Ramaiya Nikhil H. 《Abdominal imaging》2019,44(3):1083-1090
Abdominal Radiology - Serum tumor markers (STMs) play a critical role in the diagnosis, staging and follow-up of both seminomatous and nonseminomatous testicular germ cell neoplasms. Levels of... 相似文献
64.
Ebola virus disease – gaps in knowledge and practice among healthcare workers in Lagos,August 2014 下载免费PDF全文
Abisola M. Oladimeji Saheed Gidado Patrick Nguku Iruoma Genevieve Nwangwu Nikhil D. Patil Femi Oladosu Alero Ann Roberts Ndadilnasiya E. Waziri Faisal Shuaib Olukayode Oguntimehin Emmanuel Musa Abdulsalami Nasidi Peter Adewuyi Adebola Olayinka Oladoyin Odubanjo N‐FELTP Residents Gabriele Poggensee 《Tropical medicine & international health : TM & IH》2015,20(9):1162-1170
65.
TNFα and IL‐17A are differentially expressed in psoriasis‐like vs eczema‐like drug reactions to TNFα antagonists 下载免费PDF全文
66.
Rahel Thomi Christoph Schlapbach Nikhil Yawalkar Dagmar Simon Daniel Yerly Robert E. Hunger 《Experimental dermatology》2018,27(2):172-177
Hidradenitis suppurativa (HS) is an inflammatory skin disease with poorly understood immunopathogenic mechanisms. LL‐37 is an antimicrobial peptide, which is transcribed from the CAMP (cathelicidin antimicrobial peptide) gene. Previous reports showed upregulated levels of CAMP and LL‐37 in HS lesions, and therefore, the aim of this study was to compare levels of LL‐37 in HS to other inflammatory skin diseases and to establish immunomodulatory functions of LL‐37 in HS. We confirm an upregulation of the LL‐37 peptide in lesional HS skin with comparable levels as in psoriasis patients and are able to positively correlate the presence of LL‐37 in HS with the presence of T cells, macrophages, neutrophils, IFN‐γ, IL‐17, IL‐23, TNF‐α, IL‐32 and IL‐1β. Mechanistically, LL‐37 boosts the proliferation of unspecifically activated CD4+ T cells via an increased calcium signalling independent of antigen‐presenting cells. Targeting LL‐37 may therefore represent a new therapeutic option for the treatment of this recalcitrant disease, but it has to be kept in mind that LL‐37 also has an antimicrobial function. 相似文献
67.
Group I metabotropic glutamate receptors (mGluR1 and mGluR5 subtypes) are positively coupled to phosphoinositide hydrolysis through G-proteins and are densely expressed in medium-sized projection neurons of striatum. Selective activation of Group I mGluRs upregulates preproenkephalin (PPE) mRNA expression in the rat dorsal striatum. This study investigated the role of one subtype of Group I receptors, mGluR5, in the regulation of PPE mRNA expression in the rat dorsal striatum using quantitative in situ hybridization. Unilateral injection of the mGluR5 selective agonist (RS)-2-Chloro-5-hydroxyphenylglycine (CHPG) into the dorsal striatum (caudoputamen) of chronically cannulated rats at doses of 50 and 200 nmol elevated basal levels of PPE mRNA in the injected dorsal striatum. The induction of PPE mRNA was evident at 1 h, remained at 3 h, and returned to normal level 6 h after CHPG injection. Pretreatment with an mGluR5 selective antagonist 2-methyl-6-(phenylethynyl) pyridine hydrochloride (MPEP) at a dose of 10 mg/kg (i.p.) blocked CHPG-stimulated PPE expression. MPEP also attenuated PPE expression induced by dopamine D(2) receptor blockade with eticlopride (0.5 mg/kg, i.p.). Administration of MPEP alone had no significant effects on basal levels of PPE mRNA in the striatum. The results from the present study demonstrate that glutamatergic tone on mGluR5 possesses the ability to positively regulate PPE gene expression in striatal neurons in vivo. Moreover, activation of mGluR5 participates in the mediation of D(2) antagonist-induced PPE expression. 相似文献
68.
Kulkarni Vinay Joshi Smita Gupte Nikhil Gokhale Neeta 《Journal of clinical microbiology》2009,47(9):2998-2999
We report eight cases and the incidence of leprosy in human immunodeficiency virus (HIV)-infected individuals after initiation of antiretroviral treatment (ART). The incidence of leprosy in patients on ART was 5.22 per 1,000 person-years (95% confidence interval, 2.25 to 10.28). This high incidence suggests that there should be regular examination of HIV-infected individuals for clinical signs of leprosy.Although there is a declining trend in the global burden of leprosy, there are 15 countries in Asia and Africa which account for 94% of the global total of the new-case detection rate. India is one of the countries where ≥1,000 new cases of leprosy were reported during 2006 (14). Human immunodeficiency virus (HIV) and leprosy both are feared due to the associated social stigma, and leprosy can manifest as immune reconstitution inflammatory syndrome (IRIS) in HIV-infected individuals (9). The first case of leprosy-associated immune reconstitution disease was reported in 2003 for a Ugandan living in London, United Kingdom (5). Later leprosy was described as a manifestation of IRIS in many instances (8, 10).Antiretroviral treatment (ART) for HIV infection is now available in resource-poor regions where leprosy is still endemic, such as South America, Africa, and Asia, including India. India accounts for half of the world''s leprosy cases due to its population of more than 1 billion, even though a nationwide prevalence of less than 1 case/10,000 population was reported in 2005 (4). In addition, India also has the third largest burden of HIV-infected individuals (12). In spite of having a large burden of both leprosy and HIV, there are very few published reports of HIV-leprosy coinfection from India. We report eight cases of incident leprosy in HIV-infected patients who were on ART and the incidence of leprosy in HIV-infected individuals on ART.This report is from the Amrita Clinic of PRAYAS, a nongovernmental organization working on HIV/AIDS in Pune, in the state of Maharashtra, India. We retrospectively analyzed data on HIV-infected patients who initiated ART between January 2003 and December 2006 and we studied their follow-up till December 2007 to evaluate the incident cases of leprosy. ART was provided following the national guidelines for treatment of HIV infection (7).Diagnosis of leprosy was based on the clinical signs and symptoms and demonstration of acid-fast bacilli in the slit skin smears by Ziehl-Neelsen staining. All patients with leprosy received multidrug treatment per the WHO guidelines (15).Several definitions of IRIS have been utilized, each incorporating the general concept that cases of IRIS need to have an inflammatory component occurring in the setting of immune reconstitution that cannot be explained by drug toxicity or a new opportunistic infection (1, 6). We have considered leprosy manifestation after starting ART with increase in CD4+ cell count, inflammatory response as seen by neuritis, type I or type II leprosy reaction, or need for the use of steroids for the control of inflammation as a criterion for defining leprosy manifestation as IRIS. Statistical analysis was done using STATA (version 8.0).Between January 2003 and December 2006, among the 1,002 HIV-infected patients who started ART for HIV infection and were followed up till December 2007, eight incident cases of leprosy were detected. None of them had clinical evidence of leprosy at the time of initiation of ART. Table Table11 describes the details of these eight patients. All the patients except for one were males, and the mean age of the patients with leprosy was 33.8 years (standard deviation [SD], 5.1 years; range, 27 to 42 years). Four patients had paucibacillary leprosy, and four patients had multibacillary leprosy. The mean CD4+ cell count of incident leprosy cases was 326 (median, 245; SD, 255.5; range, 99 to 892). Of these eight patients, three had other opportunistic infections such as pulmonary tuberculosis, abdominal tuberculosis, and herpes zoster. The mean number of months to develop leprosy after starting ART was 13.8 months (SD, 14.3 months; range, 2 to 43 months). All eight patients completed their leprosy treatment and recovered completely. Although eight patients developed incident leprosy, six of them developed leprosy within 2 years of starting ART and two patients had delayed manifestations, with one patient developing leprosy after 28 months and the other after 43 months. These 1,002 patients on ART contributed to 1,532.5 person-years, and hence, the overall incidence of leprosy after starting ART was 5.22 per 1,000 person-years (95% confidence interval, 2.25 to 10.28).
Open in a separate windowaAbbreviations: M, male; F, female; ENL, erythema nodosum leprosum; PB, paucibacillary; MB, multibacillary; HAART, highly active ART.bPercent CD4 cell count was similar to what was seen at 6 months.To our knowledge, this is the first published report on the incidence of leprosy in HIV-infected patients on ART. ART is now more accessible in resource-poor regions where leprosy is still endemic, and reports of leprosy associated with immune reconstitution disease are increasing. This disease is most likely to be seen in India, where the HIV epidemic is growing and where 161,457 new cases of leprosy were diagnosed in 2005 alone (2). Vigilance needs to be especially high during the first several months of therapy, when the incidences of IRIS peaks, but cases continue to occur even after 1 or 2 years of therapy. Leprosy may not always manifest as IRIS, and there are a few reports of leprosy-HIV coinfection among patients who were not receiving ART (11). Difficulty in defining IRIS has been reported elsewhere (13), and we have faced similar difficulty in labeling two cases of leprosy as IRIS that developed at 28 and 43 months, respectively, after initiating ART. It is not clear if it was due to immune reconstitution or new infection, and prospective well-planned studies with longer follow-up will help in identifying the longest interval to development of IRIS.Our report shows a high incidence of leprosy in HIV-infected individuals after initiation of ART. In the same state of Maharashtra, in the general population, the National Leprosy Elimination Programme reported a total of 12,397 new cases of leprosy and the new case detection rate was 11.12 per 100,000 with the prevalence being 0.71 per 10,000 population (3).To conclude, with the availability of ART in developing countries, more and more incident leprosy cases are likely to be seen in areas where leprosy is endemic and HIV is also highly prevalent. HIV-infected individuals on ART from countries where leprosy is endemic should be regularly examined for cutaneous lesions and nerve thickness, especially during the first 2 years of starting ART, but cases may continue to occur even after 1 to 2 years of therapy. 相似文献
TABLE 1.
Details of HIV-infected patients on ART with incident leprosyaPatient no. | Age (yr) | Sex | Clinical presentation | Bacterial index | WHO classification | CD4+ cell count (cells/mm3) before HAART | CD4+ cell count (cells/mm3) 6 mo after HAART | % rise in CD4+ cell count | CD4+ cell count when leprosy was diagnosed | Time to onset of leprosy (mo) | Other associated opportunistic condition(s) |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 35 | M | Hypoaesthetic patch and nodules, ENL | 2+ | MB | 177 | 316 | 1.8 | 892 | 43 | None |
2 | 35 | M | Multiple patches in reaction, neuritis | 2+ | MB | 75 | 170 | 2.3 | 170 | 8 | Pulmonary tuberculosis, pericardial effusion |
3 | 40 | F | Hypoaesthetic patch, neuritis | 0 | PB | 85 | 251 | 3.0 | 251 | 6 | None |
4 | 31 | M | Nodules, ENL | 3+ | MB | 99 | 338 | 3.4 | 99 | 2 | Diarrhea |
5 | 31 | M | Nodules | 3+ | MB | 124 | 239 | 1.9 | 239 | 28 | None |
6 | 30 | M | Hypoaesthetic patch, ENL, neuritis | 0 | PB | 31 | 215 | 6.9 | 144 | 4 | Abdominal tuberculosis |
7 | 42 | M | Hypoaesthetic patch | 0 | PB | 331 | 548 | 4.0 | 374b | 16 | None |
8 | 27 | M | Hypoaesthetic patch with inflammation | 0 | PB | 174 | 436 | 2.5 | 436 | 5 | Herpes zoster |
69.
Cardiopulmonary ultrasound for critically ill adults improves diagnostic accuracy in a resource‐limited setting: the AFRICA trial 下载免费PDF全文
70.
Acinetobacter baumannii infections are difficult to treat due to biofilm formation. The literature shows paucity of data on A. baumannii bacteriophages and their application in biofilm control. In this report, we have isolated a new lytic bacteriophage, AB7-IBB1, infecting A. baumannii. Transmission electron microscopy revealed its resemblance to members of the family Siphoviridae, with a tail size of 240 × 10 nm and an icosahedral head 50 nm in diameter. Plaques were 3-5 mm in diameter after 24 h, increasing to 7-9 mm in three days. The phage genome size was determined to be ~75 kb. AB7-IBB1 could lyse 23 of 39 (59 %) clinical isolates of A. baumannii. It exhibited rapid adsorption (>99 % adsorbed in 5 min), a latency period of 30 min and a burst size of 125 PFU/infected cell. The phage affected A. baumannii biofilm formation on an abiotic surface (polystyrene) and a biotic surface (human embryonic kidney 293 cell line). It also showed biofilm control ability on an abiotic surface (polystyrene). FESEM visualization studies confirmed the detrimental effect of phage AB7-IBB1 on host biofilm. In conclusion, this study reports a novel lytic bacteriophage, AB7-IBB1, belonging to family Siphoviridae, with promising anti-biofilm properties. 相似文献